Formulation Development
Facility Update From Sever Pharma Solutions
In 2024, our Putnam site fully commissioned and qualified two new High Potent API processing suites, one for development and one for GMP manufacturing. These…
Cytovation Raises $6M to Advance Phase 2 Development of CY-101 in Adrenocortical Carcinoma to First Clinical Readouts
Cytovation ASA recently announced it has raised NOK62 million (US$6m) largely from existing investors, led by Sandwater. These funds will be used to advance CY-101…
Boehringer Ingelheim & Tessellate Bio Partner to Develop First-in-Class Precision Treatments for People With Hard-to-Treat Cancers
Boehringer Ingelheim and Tessellate Bio have entered into a research collaboration and global license agreement. Jointly the partners will focus on the development of first-in-class,…
BPGbio Presents New Research on Tumor Metabolism, Immunotherapy & Diagnostics
BPGbio, Inc. recently announced the presentation of seven presentations at the American Association for Cancer Research (AACR) Annual Meeting, taking place April 25-30, 2025, in…
Tiziana Life Sciences Announces University of Massachusetts Commences Dosing Intranasal Foralumab in Phase 2 Multiple Sclerosis Trial
Tiziana Life Sciences, Ltd. recently announced dosing has commenced at the fourth clinical site in its ongoing Phase 2 trial evaluating intranasal foralumab in patients…
Bluejay Therapeutics Announces Upcoming Presentation of Preclinical Data in Metabolic Dysfunction-Associated Steatohepatitis
Bluejay Therapeutics recently announced it will present new preclinical data on the characterization of BJT-188, a liver-targeted fatty acid synthase (FASN) inhibitor being investigated for the…
Kymera Therapeutics Announces First Patient Dosed in BROADEN Phase 1b Atopic Dermatitis Clinical Trial of First-in-Class Oral STAT6 Degrader
Kymera Therapeutics, Inc. recently announced it recently initiated dosing in its BroADen Phase 1b clinical trial evaluating KT-621, an oral, highly selective, potent degrader of…
March Biosciences Announces First Patient Dosed in Phase 2 Clinical Trial of First-in-Class CD5 CAR-T Cell Therapy for T-Cell Lymphoma
March Biosciences recently announced the first patient has been dosed in its Phase 2 clinical trial evaluating MB-105, a first-in-class CD5-targeted CAR-T cell therapy for…
Ocean Biomedical Expands Into Energy & Digital Asset Sectors to Accelerate Growth & Shareholder Value
Ocean Biomedical, Inc. recently announced a strategic expansion of its business operations to include power infrastructure development and a cryptocurrency treasury strategy, including Bitcoin and Solana. This move comes…
Kindeva Bolsters Executive Team With Chief Quality Officer
Kindeva recently announced the appointment of Melanie Cerullo as Chief Quality Officer to drive its quality, compliance and regulatory strategy. With a proven track record in…
Vaccinex to Report Promising New Clinical Data Revealing Pepinemab’s Unique Mechanism to Enhance Immunotherapy
Vaccinex, Inc. recently announced it will present exciting new data characterizing the unique mechanism of pepinemab to enhance immune responses to checkpoint therapies, corresponding with…
Ligand Subsidiary Pelthos Therapeutics to Combine With Channel Therapeutics
Ligand Pharmaceuticals Incorporated and Channel Therapeutics Corporation recently announced the signing of a definitive merger agreement to combine Ligand’s wholly owned subsidiaries, Pelthos Therapeutics Inc.…
eschbach Introduces SAMI: The Next Evolution in AI-Empowered Process Manufacturing
Global software developer eschbach, the provider of the Shiftconnector enterprise manufacturing platform for process manufacturing, is proud to unveil a powerful new chat feature within…
Lonza Joins Centre for Continuous Manufacturing & Advanced Crystallisation to Enhance Service Offering
Lonza, a global development and manufacturing partner to the pharmaceutical and biotech markets, recently announced it has joined CMAC, a world leading centre for medicines…
Cullinan Therapeutics Receives Approval From EMA to Initiate Phase 1 Trial of a Bispecific CD19 T Cell Engager Administered Subcutaneously in Patients With RA
Cullinan Therapeutics, Inc. recently announced the European Medicines Agency (EMA) approved the company’s Clinical Trial Application (CTA) for CLN-978. The Phase 1 clinical trial will…
AccuStem Sciences Signs Agreement to Access Blood Samples From Lung Cancer Screening Trial to Expedite MSC Commercialization Plan
AccuStem Sciences, Inc.recently announced a development agreement to access blood samples from the multi-institutional, prospective, randomized Rete Italiana di Screening Polmonare (RISP) clinical trial. This…
Q32 Bio Doses First Patients in Both Part A Open-Label Extension & Part B of SIGNAL-AA Phase 2a Trial Evaluating Bempikibart in Alopecia Areata
Q32 Bio Inc. recently announced it has dosed the first patients in both the Part A open-label extension (OLE) and Part B of the SIGNAL-AA…
Salarius Pharmaceuticals Merger Partner, Decoy Therapeutics, Appoints Renowned MIT Professor Robert S. Langer to its Scientific Advisory Board
Decoy Therapeutics, Inc. recently announced Massachusetts Institute of Technology (MIT) Professor and Moderna Co-founder Robert S. Langer, ScD will join the company’s Scientific Advisory Board…
Addgene Adds Science & Tech Leaders to its Management Team & Board of Directors
Addgene recently announced the expansion of its management team and Board of Directors with numerous industry leaders. These key appointments support Addgene’s growth strategy and illustrate…
Conduit Pharmaceuticals Announces Leadership Changes
Conduit Pharmaceuticals Inc. recently announced key leadership changes to support the company’s next phase of growth and execution. Dr. Andrew Regan, the founder and initial…
